Axsome, migraine

US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Truist raises Axsome Therapeutics stock target to $190 on Symbravo approval
Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's shares.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
FDA Approves Symbravo for Acute Migraine Treatment
The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the treatment of acute migraine with or without aura in adults,
Axsome Therapeutics' SWOT analysis: CNS drug developer's stock poised for growth
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has been making significant strides in its product pipeline and commercial efforts.
Buy Rating for Axsome Therapeutics Driven by Symbravo Approval and Strategic Market Approach
Analyst Ami Fadia of Needham maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of
Axsome Therapeutics price target raised to $137 from $122 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $137 from $122 and keeps an Outperform rating ...
FiercePharma3d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Zacks.com on MSN10d
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...
Axsome Therapeutics price target raised to $190 from $180 at Truist
Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares.
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...
Axsome Shares Up Post Market After Hitting Record High on FDA Approval
Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients ...
Axsome Therapeutics (NASDAQ:AXSM) Given Outperform Rating at Royal Bank of Canada
Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a ...
RBC Capital lifts Axsome stock target to $143, sees launch potential
RBC Capital Markets analyst Leonid Timashev increased the price target for Axsome Therapeutics (NASDAQ:AXSM) to $143 from $139, while keeping an Outperform rating on the stock. According to ...